GT201400056A - Proteínas de función dual para tratar trastornos metabolicos - Google Patents

Proteínas de función dual para tratar trastornos metabolicos

Info

Publication number
GT201400056A
GT201400056A GT201400056A GT201400056A GT201400056A GT 201400056 A GT201400056 A GT 201400056A GT 201400056 A GT201400056 A GT 201400056A GT 201400056 A GT201400056 A GT 201400056A GT 201400056 A GT201400056 A GT 201400056A
Authority
GT
Guatemala
Prior art keywords
metabolic disorders
dual function
treat metabolic
function proteins
disorders associated
Prior art date
Application number
GT201400056A
Other languages
English (en)
Inventor
Brian R Boettcher
Shari L Caplan
Susan E Cellitti
Douglas S Daniels
Hamamatsu Norio
Geierstanger Bernhard Hubert
Licht Stuart
Loew Andreas
Weldon Stephen Craig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47023090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201400056(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201400056A publication Critical patent/GT201400056A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A LA IDENTIFICACIÓN DE NUEVAS PROTEÍNAS QUE COMPRENDEN EL FACTOR DE CRECIMIENTO DE FIBROBLASTOS 21 (FGF21) Y OTROS REGULADORES METABÓLICOS, INCLUYENDO VARIANTES DE LOS MISMOS, CONOCIDOS POR MEJORAR LOS PERFILES METABÓLICOS EN SUJETOS EN QUIENES SE ADMINISTREN. TAMBIÉN SE DIVULGAN MÉTODOS PARA TRATAR TRASTORNOS ASOCIADOS CON EL FGF21, TRASTORNOS ASOCIADOS CON GLP-1, Y TRASTORNOS ASOCIADOS CON EXENDINA-4, INCLUYENDO CONDICIONES METABÓLICAS.
GT201400056A 2011-09-26 2014-03-26 Proteínas de función dual para tratar trastornos metabolicos GT201400056A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161539290P 2011-09-26 2011-09-26

Publications (1)

Publication Number Publication Date
GT201400056A true GT201400056A (es) 2015-09-23

Family

ID=47023090

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201400056A GT201400056A (es) 2011-09-26 2014-03-26 Proteínas de función dual para tratar trastornos metabolicos

Country Status (26)

Country Link
US (2) US9458214B2 (es)
EP (1) EP2764019B1 (es)
JP (1) JP6152380B2 (es)
KR (1) KR102217254B1 (es)
CN (2) CN104024273B (es)
AP (1) AP2014007544A0 (es)
AR (1) AR088165A1 (es)
AU (1) AU2012316132A1 (es)
BR (1) BR112014007086A2 (es)
CA (1) CA2849760A1 (es)
CL (1) CL2014000737A1 (es)
CO (1) CO6920258A2 (es)
CR (1) CR20140141A (es)
CU (1) CU20140035A7 (es)
EA (1) EA201490697A1 (es)
GT (1) GT201400056A (es)
IL (1) IL231647A0 (es)
MA (1) MA35507B1 (es)
MX (1) MX350840B (es)
PE (1) PE20141542A1 (es)
SG (1) SG11201400596QA (es)
TN (1) TN2014000110A1 (es)
TW (1) TW201315742A (es)
UY (1) UY34347A (es)
WO (1) WO2013049234A2 (es)
ZA (1) ZA201401699B (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
HUE058896T2 (hu) 2010-10-01 2022-09-28 Modernatx Inc N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
MY163674A (en) 2011-07-01 2017-10-13 Ngm Biopharmaceuticals Inc Compositions, uses and method for treatment of metabolic disorders and diseases
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
TWI593708B (zh) 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質
TW201315742A (zh) 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
KR102238317B1 (ko) 2012-05-17 2021-04-12 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
TW201420606A (zh) * 2012-08-22 2014-06-01 Lilly Co Eli 同源二聚體蛋白
AU2013311777B2 (en) * 2012-09-07 2018-02-01 Sanofi Fusion proteins for treating a metabolic syndrome
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
AU2013352363B2 (en) 2012-11-28 2018-04-12 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
DK2938740T3 (da) 2012-12-27 2022-06-20 Ngm Biopharmaceuticals Inc Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
EP2941267B1 (en) * 2013-01-03 2022-11-16 Oramed Ltd. Compositions for use in treating nafld
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
SG11201602870YA (en) 2013-10-28 2016-05-30 Ngm Biopharmaceuticals Inc Cancer models and associated methods
UA119863C2 (uk) 2014-01-24 2019-08-27 Нгм Біофармасьютікалс, Інк. Антитіло або його фрагмент, що зв'язується з бета-клото
JP6712230B2 (ja) * 2014-03-11 2020-06-17 ノバルティス アーゲー リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法
PT3129467T (pt) * 2014-04-11 2020-02-04 Univ Catholique Louvain Ilhéus de porco transgénicos e seus usos para tratar a diabetes
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
AU2015277438B2 (en) 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
GB201411320D0 (en) * 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
CN107108711B (zh) 2014-10-23 2021-11-23 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
EA037478B1 (ru) 2015-08-04 2021-04-01 Дьюк Юниверсити Генетически кодируемые внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения
TW201718629A (zh) * 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
KR102668200B1 (ko) * 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
KR102670157B1 (ko) * 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
CA3010756A1 (en) 2016-01-13 2017-07-20 Novo Nordisk A/S Egf(a) analogues with fatty acid substituents
US11318186B2 (en) 2016-05-25 2022-05-03 Board Of Regents, The University Of Texas System Use of FGF21 in methods of increasing exocrine pancreatic secretion
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
CN106317226B (zh) 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
AU2017315459B2 (en) 2016-08-26 2023-06-29 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
US11135301B2 (en) 2016-09-14 2021-10-05 Duke University Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs
JP2020500150A (ja) 2016-09-23 2020-01-09 デューク ユニバーシティ 下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド
US11179440B2 (en) 2016-11-10 2021-11-23 Yuhan Corporation Pharmaceutical composition containing FGF21 mutant fusion protein and method for treating hepatitis, hepatic fibrosis, and hepatic cirrhosis
AU2017363321B2 (en) 2016-11-22 2023-09-28 Klotho Therapeutics, Inc. Novel recombinant Klotho proteins and compositions and methods involving the same
CA3047862A1 (en) * 2016-12-22 2018-06-28 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
CN108440668A (zh) * 2017-02-16 2018-08-24 瑞阳(苏州)生物科技有限公司 Fgf21与igf-1的融合蛋白及其应用
US20220127322A1 (en) * 2017-03-14 2022-04-28 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
US11560416B2 (en) * 2017-04-21 2023-01-24 Yuhan Corporation Method for producing dual function proteins and its derivatives
US11554097B2 (en) 2017-05-15 2023-01-17 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
US11680083B2 (en) 2017-06-30 2023-06-20 Duke University Order and disorder as a design principle for stimuli-responsive biopolymer networks
JP7339236B2 (ja) 2017-07-19 2023-09-05 ノヴォ ノルディスク アー／エス 二機能性化合物
EP3706774A4 (en) * 2017-11-06 2021-09-08 Shire-NPS Pharmaceuticals, Inc. GLP-2 ANALOGUES AND PEPTIBODIES FOR USE BEFORE, DURING OR AFTER SURGICAL PROCEDURE
CN115109166A (zh) * 2017-11-24 2022-09-27 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
CN111518770B (zh) * 2017-12-19 2023-01-06 北京吉源生物科技有限公司 一种表达glp1和fgf21的干细胞及其用途
IL275499B2 (en) * 2017-12-22 2024-03-01 Novartis Ag Methods for treating metabolic disorders with FGF21 variants
CN110028587B (zh) * 2018-01-11 2021-10-08 安源医药科技（上海）有限公司 用于调节血糖和脂质的增效型双功能蛋白
US11679143B2 (en) 2018-02-08 2023-06-20 Sunshine Lake Pharma Co., Ltd. FGF21 variant, fusion protein and application thereof
CU24554B1 (es) * 2018-05-07 2021-11-04 Ct Inmunologia Molecular Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1
JP2021528422A (ja) * 2018-06-21 2021-10-21 サノフイＳａｎｏｆｉ 最適化された活性比を有するｆｇｆ２１化合物／ｇｌｐ−１ｒアゴニストの組合せ
EP3817720A2 (en) 2018-07-03 2021-05-12 Bristol-Myers Squibb Company Fgf21 formulations
US11649275B2 (en) 2018-08-02 2023-05-16 Duke University Dual agonist fusion proteins
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
EP3927815A2 (en) * 2019-02-20 2021-12-29 Novo Nordisk A/S Aminoacyl-trna synthetases and uses hereof
CN114853908B (zh) * 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
US20220332780A1 (en) 2019-09-10 2022-10-20 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
CN116925237A (zh) 2019-12-31 2023-10-24 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
WO2021139744A1 (en) * 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
US11981718B2 (en) * 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
CN113105561B (zh) * 2021-04-30 2021-12-03 江南大学 一种双靶点融合蛋白的制备方法和应用
KR102631925B1 (ko) * 2021-06-10 2024-02-01 토드제약 주식회사 신규 fgf21 변이체 개발 및 이의 생산기법과 용도
WO2024102634A1 (en) * 2022-11-07 2024-05-16 Bp Asset Ix, Inc. Fgf21 protein variant for the treatment of nash

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
EP0587255A1 (en) 1986-05-05 1994-03-16 The General Hospital Corporation Insulinotropic hormone
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE3889853D1 (de) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
PT944648E (pt) 1996-08-30 2007-06-26 Novo Nordisk As Derivados do glp-1.
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
ATE446365T1 (de) 1999-11-18 2009-11-15 Novartis Vaccines & Diagnostic Menschliches fgf-21 gen und genexpressionsprodukte
DE60030769T2 (de) 1999-12-23 2007-10-25 Zymogenetics, Inc., Seattle Verfahren zur behandlung von entzündungen
JP2005502322A (ja) 2001-04-19 2005-01-27 ザ スクリップス リサーチ インスティテュート 非天然アミノ酸のインビボ組込み
ATE522548T1 (de) * 2003-11-13 2011-09-15 Hanmi Holdings Co Ltd Verfahren zur massenproduktion der konstanten region von immunglobulin
BRPI0416683A (pt) * 2003-12-10 2007-01-30 Lilly Co Eli muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21
EP1797127B1 (en) * 2004-09-24 2017-06-14 Amgen Inc. Modified fc molecules
EP1846019A2 (en) 2005-01-21 2007-10-24 Eli Lilly And Company Method for treating cardiovascular disease
EP2068909B1 (en) 2007-03-30 2012-04-25 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
WO2009020802A2 (en) 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
EA201990619A1 (ru) 2008-10-10 2019-07-31 Амген Инк. Fgf21 мутанты и их применение
ES2477543T3 (es) 2008-10-24 2014-07-17 Irm Llc Pirrolina-carboxi-lisina generada biosintéticamente y modificaciones de proteínas específicas de sitio mediante derivatización química de restos de pirrolina-carboxi-lisina y pirrolisina
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
HUE031900T2 (en) 2008-12-10 2017-08-28 Glaxosmithkline Llc Pharmaceutical compositions containing Albiglutide
BRPI1007313A2 (pt) 2009-01-23 2016-02-10 Novo Nordisk As derivados de fgf21 com ligante de albumina a-b-c-d-e e seu uso.
CN101812474A (zh) * 2009-02-25 2010-08-25 李慎涛 骨保护素-热休克蛋白65融合蛋白的制备及其应用
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
US8188040B2 (en) 2009-05-05 2012-05-29 Amgen Inc. FGF21 mutants and uses thereof
CN102802657A (zh) 2009-06-11 2012-11-28 诺沃-诺迪斯克有限公司 用于治疗2型糖尿病的glp-1和fgf21组合
CN101993485B (zh) * 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
CN101993496B (zh) * 2009-08-20 2013-06-05 重庆富进生物医药有限公司 双重调节血糖血脂融合蛋白及其制法和用途
KR20120107122A (ko) 2009-12-22 2012-09-28 노파르티스 아게 치료법에서 사용하기 위한 ４가 ｃｄ４７―항체 불변 영역 융합 단백질
EP2460527A1 (en) 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
TWI593708B (zh) 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質
TW201315742A (zh) 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
JP6712230B2 (ja) 2014-03-11 2020-06-17 ノバルティス アーゲー リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法

Also Published As

Publication number Publication date
UY34347A (es) 2013-04-30
AU2012316132A1 (en) 2014-04-17
BR112014007086A2 (pt) 2017-03-28
JP2014527986A (ja) 2014-10-23
MX350840B (es) 2017-09-19
SG11201400596QA (en) 2014-09-26
IL231647A0 (en) 2014-05-28
ZA201401699B (en) 2015-04-29
MX2014003676A (es) 2015-03-20
EA201490697A1 (ru) 2014-11-28
WO2013049234A3 (en) 2014-01-03
CA2849760A1 (en) 2013-04-04
CN104024273A (zh) 2014-09-03
MA35507B1 (fr) 2014-10-02
TN2014000110A1 (en) 2015-07-01
WO2013049234A2 (en) 2013-04-04
JP6152380B2 (ja) 2017-06-21
US20130129724A1 (en) 2013-05-23
TW201315742A (zh) 2013-04-16
CU20140035A7 (es) 2014-08-28
KR20140069249A (ko) 2014-06-09
CN104024273B (zh) 2016-10-12
US10669323B2 (en) 2020-06-02
AR088165A1 (es) 2014-05-14
EP2764019B1 (en) 2019-04-03
CR20140141A (es) 2014-07-15
US20170166621A1 (en) 2017-06-15
PE20141542A1 (es) 2014-10-31
CL2014000737A1 (es) 2014-10-03
EP2764019A2 (en) 2014-08-13
CN106432510A (zh) 2017-02-22
US9458214B2 (en) 2016-10-04
AP2014007544A0 (en) 2014-03-31
CO6920258A2 (es) 2014-04-10
KR102217254B1 (ko) 2021-02-19

Similar Documents

Publication Publication Date Title
GT201400056A (es) Proteínas de función dual para tratar trastornos metabolicos
UY39119A (es) Proteínas de fusión para tratar trastornos metabólicos
BR112016009889A2 (pt) ?compostos agonistas duplos gip-glp-1 e métodos?
CR20130234A (es) Métodos de tratamiento de trastornos asociados con el fgf21
MX2020002184A (es) Composiciones y metodos para modular la expresion de la apolipoproteina (a).
ECSP14013152A (es) Compuestos inhibidores de metaloenzimas
GT201300215A (es) Inhibidores de glucosilceramida sintasa
PE20150201A1 (es) Proteinas del factor 21 de crecimiento del fibroblasto
BR112014002884A2 (pt) composição para estimulação ovariana controlada
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
AR087956A1 (es) METODOS Y COMPOSICIONES QUE MODULAN ACETIL-CoA CARBOXILASA PARA EL CONTROL DE MALEZAS
BR112013020798A2 (pt) terapia de combinação do inibidor mtor /jak
WO2012125408A8 (en) Pegylated apelin and uses thereof
EA201390704A1 (ru) Соединения, ингибирующие металлоферменты
BR112013025777A2 (pt) imidazopiridazinas como inibidores da quinase akt
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
CL2018001221A1 (es) Modular la expresión de apolipoproteína (a)
BR112014004224A2 (pt) aparelhos e métodos para tratamento de estacas de caules de cana-de açúcar
BR112014000889A2 (pt) tratamento para hipoxia
IN2014MN00226A (es)
ES2586805T3 (es) Análogos de péptidos para tratar enfermedades y trastornos
BR112016001009A2 (pt) nova proteína de ornitina descarboxilase modificada e sua utilização